Published in Blood on September 15, 1997
Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood (2007) 1.73
Pathogenesis of experimental rhesus cytomegalovirus infection. J Virol (1999) 1.50
Replication of murine cytomegalovirus in differentiated macrophages as a determinant of viral pathogenesis. J Virol (1999) 1.42
KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in vitro and in vivo. Blood (2006) 1.37
Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. J Virol (2005) 1.32
Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus. J Virol (2009) 1.29
Experimental human cytomegalovirus latency in CD14+ monocytes. Proc Natl Acad Sci U S A (2010) 1.26
Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells. PLoS Pathog (2013) 1.12
Human herpesvirus 6 latently infects early bone marrow progenitors in vivo. J Virol (1999) 1.08
Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells. J Virol (2002) 1.08
Viral interleukin-10 expressed by human cytomegalovirus during the latent phase of infection modulates latently infected myeloid cell differentiation. J Virol (2011) 1.06
Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology (2009) 1.04
Innate immune responses to cytomegalovirus infection in the developing mouse brain and their evasion by virus-infected neurons. Am J Pathol (2002) 1.03
Reversal of human cytomegalovirus major immediate-early enhancer/promoter silencing in quiescently infected cells via the cyclic AMP signaling pathway. J Virol (2007) 1.01
Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model. J Virol (2012) 0.99
Chromatin-mediated regulation of cytomegalovirus gene expression. Virus Res (2010) 0.97
Monitoring immediate-early gene expression through firefly luciferase imaging of HRS/J hairless mice. BMC Physiol (2003) 0.96
HCMV protein LUNA is required for viral reactivation from latently infected primary CD14⁺ cells. PLoS One (2012) 0.92
Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo. J Virol (2013) 0.91
Hematopoietic stem cells and retroviral infection. Retrovirology (2010) 0.91
Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: implications for hematopoiesis, self-renewal and differentiation potential. Virology (2006) 0.90
Human Cytomegalovirus Latency: Approaching the Gordian Knot. Annu Rev Virol (2016) 0.86
The intimate relationship between human cytomegalovirus and the dendritic cell lineage. Front Microbiol (2014) 0.85
Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation. J Gen Virol (2012) 0.85
Human Cytomegalovirus (HCMV) - Revised. Transfus Med Hemother (2010) 0.83
Mitogen and stress activated kinases act co-operatively with CREB during the induction of human cytomegalovirus immediate-early gene expression from latency. PLoS Pathog (2014) 0.82
Human cytomegalovirus manipulation of latently infected cells. Viruses (2013) 0.81
Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients. J Gen Virol (2014) 0.80
Inhibition of the FACT Complex Reduces Transcription from the Human Cytomegalovirus Major Immediate Early Promoter in Models of Lytic and Latent Replication. J Virol (2016) 0.79
Functional annotation of human cytomegalovirus gene products: an update. Front Microbiol (2014) 0.79
Dynamics of Human Cytomegalovirus Infection in CD34+ Hematopoietic Cells and Derived Langerhans-Type Dendritic Cells. J Virol (2015) 0.78
Cytomegalovirus latency and reactivation: recent insights into an age old problem. Rev Med Virol (2015) 0.78
HCMV requires EGFR signaling to enter and initiate the early steps in the establishment of latency in CD34+ human progenitor cells. J Virol (2016) 0.76
HCMV Displays a Unique Transcriptome of Immunomodulatory Genes in Primary Monocyte-Derived Cell Types. PLoS One (2016) 0.76
Activation of Langerhans-Type Dendritic Cells Alters Human Cytomegalovirus Infection and Reactivation in a Stimulus-Dependent Manner. Front Microbiol (2016) 0.75
AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation (2000) 4.80
Environmental and societal factors affect food choice and physical activity: rationale, influences, and leverage points. Nutr Rev (2001) 3.94
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia (2011) 2.82
Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (2000) 2.42
Cytomegalovirus replication in cells pretreated with 5-iodo-2'-deoxyuridine. J Virol (1973) 2.41
Cytomegalovirus: conversion of nonpermissive cells to a permissive state for virus replication. Science (1973) 2.15
The development by cytomegalovirus-infected cells of binding affinity for normal human immunoglobulin. J Immunol (1976) 2.12
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia (2010) 2.01
AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke (2000) 1.90
Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood (2001) 1.89
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia (2013) 1.84
Correction of the PNH defect by GPI-anchored protein transfer. Blood (1998) 1.55
Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer (1984) 1.49
Summary of a scientific conference on preventive nutrition: pediatrics to geriatrics. Circulation (1999) 1.46
Suppression of normal human hematopoiesis by cytomegalovirus in vitro. Exp Hematol (1993) 1.43
UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia (2008) 1.39
Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia (2007) 1.37
Identification of persistent RNA-DNA hybrid structures within the origin of replication of human cytomegalovirus. J Virol (1998) 1.34
Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol (1995) 1.33
Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. J Virol (2005) 1.32
Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood (1996) 1.32
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia (2012) 1.31
New hantaviruses causing hantavirus pulmonary syndrome in central Argentina. Lancet (1997) 1.27
Transcription of the human cytomegalovirus genome in productively infected cells. J Gen Virol (1981) 1.27
Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest (2001) 1.25
TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia (2009) 1.23
Infection of mononucleated phagocytes with human cytomegalovirus. Virology (1993) 1.23
Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood (1998) 1.19
Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. Leukemia (2007) 1.19
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene (2012) 1.16
Effects of tumor necrosis factor alpha on sin nombre virus infection in vitro. J Virol (2000) 1.12
Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia (2013) 1.10
Persistence of cytomegalovirus in human lymphoblasts and peripheral leukocyte cultures. Infect Immun (1977) 1.06
Comparison of the polypeptides of several strains of human cytomegalovirus. J Gen Virol (1977) 1.05
Physical activity, genetic, and nutritional considerations in childhood weight management. Med Sci Sports Exerc (1998) 1.04
Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood (1997) 1.04
Human cytomegalovirus alters interleukin-6 production by endothelial cells. Blood (1994) 1.03
Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J (2012) 1.02
Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol (2001) 1.02
Hypocholesterolemic effect of yogurt and milk. Am J Clin Nutr (1979) 1.01
Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in haemopoietic cells. Br J Haematol (1997) 0.98
Differential gene expression in hematopoietic progenitors from paroxysmal nocturnal hemoglobinuria patients reveals an apoptosis/immune response in 'normal' phenotype cells. Leukemia (2005) 0.98
Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol (1997) 0.97
Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria. Leukemia (2010) 0.96
Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J (2013) 0.93
Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia (2005) 0.92
Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients. AIDS (1997) 0.91
Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant (2007) 0.90
Analysis of human cytomegalovirus nucleoprotein complexes. J Virol (1982) 0.90
Chromosomal organization of the herpes simplex virus type 2 genome. Virology (1982) 0.90
Phylogenetic relationships of dengue-1 viruses from Argentina and Paraguay. Arch Virol (2002) 0.90
Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation. Br J Haematol (2008) 0.88
CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors. Leukemia (2012) 0.88
Nutrition and cancer education: ten years of progress. J Cancer Educ (2000) 0.87
In vitro infection of megakaryocytes and their precursors by human cytomegalovirus. Blood (2000) 0.87
Cytomegalovirus-specific regulatory and effector T cells share TCR clonality--possible relation to repetitive CMV infections. Am J Transplant (2011) 0.87
Generation of a nude mouse tumor model for in vivo replication of human cytomegalovirus. J Infect Dis (1998) 0.86
Summary and recommendations from the American Health Foundation's Expert Panel on Healthy Weight. Am J Clin Nutr (1996) 0.86
Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "Why? Why? Why?". J Clin Invest (2000) 0.86
Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome. Leukemia (2007) 0.84
Apoptosis induced by human cytomegalovirus infection can be enhanced by cytokines to limit the spread of virus. Exp Hematol (1999) 0.84
Demonstration of a cellular inhibitor of Epstein-Barr and cytomegalovirus synthesis. Virology (1975) 0.84
Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2008) 0.84
Isolation of infectious bovine rhinotracheitis virus from the soft-shelled tick, Ornithodoros coriaceus. Science (1982) 0.83
Hypocupremia and bone marrow failure. Haematologica (2008) 0.83
The role of interleukin-converting enzyme in Fas-mediated apoptosis in HIV-1 infection. J Clin Invest (1998) 0.82
Hematopoietic chimerism in sheep and nonhuman primates by in utero transplantation of fetal hematopoietic stem cells. Blood Cells (1991) 0.82
Methodological issues in weight cycling. Ann Behav Med (1996) 0.82
Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. Leukemia (1998) 0.82
Impact of immunogenetic polymorphisms in bone marrow failure syndromes. Mini Rev Med Chem (2011) 0.82
Hematopoietic inhibition by interferon-gamma is partially mediated through interferon regulatory factor-1. Blood (1995) 0.82
Enhancement of deoxyguanosine kinase activity in human lung fibroblast cells infected with human cytomegalovirus. Mol Cell Biochem (1984) 0.82
Persistence of human cytomegalovirus DNA sequences without cell-virus homology in human placental explants in culture. Int J Fertil (1990) 0.81
Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood (1998) 0.81
Inhibition of interleukin-1beta-converting enzyme in human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential. Exp Hematol (1998) 0.81
Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant. Bone Marrow Transplant (1999) 0.80
Constitution and telomere dynamics of bone marrow stromal cells in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant (2003) 0.79
Perivascular stromal cells as a potential reservoir of human cytomegalovirus. Am J Transplant (2014) 0.78
Prolonged hematopoietic chimerism in normal mice transplanted in utero with human hematopoietic stem cells. Pathobiology (1998) 0.78
Reversible response to puromycin and some characteristics of the uptake and use of amino acids by unfertilized sea urchin eggs. Biol Bull (1970) 0.77
Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia (2013) 0.77
Late relapse from complete remission in nodular and diffuse histiocytic lymphoma. Cancer (1983) 0.77
The role of FAS-mediated apoptosis in chronic myelogenous leukemia. Leuk Lymphoma (2000) 0.77
Multivariate analysis of factors associated with outcome of treatment for adults with acute myelogenous leukemia. Cancer (1984) 0.77
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia (2015) 0.76
Nitric oxide and cell survival: megakaryocytes say "NO". J Lab Clin Med (2001) 0.76
CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia. Blood Cancer J (2013) 0.76
Viruses and bone marrow failure. Schweiz Med Wochenschr Suppl (1991) 0.75
Partial characterization of a herpes-type virus (K9V) derived from Kaposi's sarcoma. J Natl Cancer Inst (1977) 0.75
Cell DNA induction by human cytomegalovirus. IARC Sci Publ (1978) 0.75
Labelling of nucleotide pools in sea urchin eggs. Exp Cell Res (1969) 0.75
Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome. Leukemia (2017) 0.75
Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis (2013) 0.75
Diet controversies in lipid therapy. J Cardiovasc Nurs (2000) 0.75